Sectra AB (SECT-B) Fair Value & Analysis
Healthcare · SE · Market cap 53.0B SEK
Fair value as of: Aug 13, 2026
From 24 valuation models · updated today
Share price −2.3% over the past month.
A solid business, but screening 76% overvalued on our models.
What matters now
- A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (kr 81.10). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 104.06 – kr 370.75 · fair‑value band kr 51.81 – kr 81.10 · the kr 278.40 price screens above the kr 66.81 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Sectra AB (SECT-B) currently trades at kr 278.40, while our model-based Fair Value estimate is kr 66.81, implying the stock looks roughly 76.0% overvalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Sectra AB generated revenue of 3.6B SEK at a net margin of 15.5%. Revenue grew 13.0% year over year. It earns a return on equity of 27.8%. The balance sheet holds a net cash position of 1.7B SEK. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 51.81 (bear case) to kr 81.10 (bull case); at kr 278.40, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 61% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -76%, SECT-B screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (kr 90.75) versus Asset-Based (kr 7.98). Highest evidence: Growth DCF (80).
Notify me when SECT-B reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 51
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sectra AB (publ) provides solutions for medical IT and cybersecurity sectors in Sweden, the United Kingdom, the Netherlands, and rest of Europe. The company operates through Imaging IT Solutions, Secure Communications, and Business Innovation segments.
Full company description
Sectra AB (publ) provides solutions for medical IT and cybersecurity sectors in Sweden, the United Kingdom, the Netherlands, and rest of Europe. The company operates through Imaging IT Solutions, Secure Communications, and Business Innovation segments. The Imaging IT Solutions segment develops and sells medical IT systems and services for managing, archiving, and presenting various types of medical images and patient information, as well as for operational follow-up and radiation dose monitoring; and maintenance and consulting services. The Secure Communications segment develops and sells products and services for secure voice and data communications, and project-based development, as well as security and threat analyses, and system monitoring services for control systems. The Business Innovation segment develops and sells IT systems for planning and monitoring orthopedic surgery; products for medical education and research projects; and IT support services for precision diagnostics in cancer care. It serves hospitals and private clinic chains. Sectra AB (publ) was incorporated in 1957 and is headquartered in Linköping, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sectra AB reported revenue of kr 3.5B in FY2026 versus kr 1.9B in FY2022, a compound +16.1%/yr. Reported net income was kr 564M in FY2026, compounding +15.7%/yr from FY2022.
of which total revenue +13.3 pp · buybacks/dilution −0.1 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
SECT-B screens 76% overvalued. Compare with Abbott Laboratories, →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Hennick Humber Hospital in Canada has selected Sectra One Cloud to speed up patient diagnostics with improved radiology workflows
- Sectra achieves the highest level of security attestation for healthcare providers adopting cloud services in Germany
- Dayton Children's Hospital goes live with Sectra's ophthalmology solution to unify imaging across specialties
- Sectra publishes Annual Report and Sustainability Report for 2025/2026
Peer Group
Medical Devices · 349 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| CLASSYS Inc 214150 | 39,700 KRW | 20,415 KRW | -49% |
Compare Sectra AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sectra AB (SECT-B) overvalued or undervalued?
What is the fair value of SECT-B?
What is the quality score of SECT-B?
What is the revenue of Sectra AB (SECT-B)?
What is the net profit margin of SECT-B?
Does Sectra AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sectra AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.